Neuro-Ophthalmologic Manifestations of Neurodegenerative Disease in Childhood

  • Michael C. Brodsky


Neurodegenerative disorders in children pose a unique diagnostic challenge. Unlike many genetic syndromes, the clinical manifestations of childhood neurodegenerative diseases are often nonspecific and show considerable overlap. Pathognomonic clinical signs are rare. Many of these conditions are uncommon, and extensive clinical experience is generally lacking, even in tertiary referral centers. To further complicate matters, these children often present in the early stages of their illness, when evidence of progression is questionable and motor or cognitive impairment is relatively mild. It is only with extended observation that both clinical and neuroimaging abnormalities evolve to suggest a limited set of diagnostic possibilities. These children usually require repeated observation by a multidisciplinary team of neurologists, neuroimaging specialists, neuro-ophthalmologists, and geneticists before a specific diagnosis is established.


Enzyme Replacement Therapy Gauche Disease Visual Evoke Potential Optic Atrophy Canavan Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Abraham FA, Yatziv S, Russell A, et al. Electrophysiological and psychological findings in Hunter syndrome. Arch Ophthalmol. 1974;91:181–186.PubMedGoogle Scholar
  2. 2.
    Accardo AP, Pensiero S, Perssutti P. Saccadic analysis for early identification of neurological involvement in Gaucher disease. Ann NY Acad Sci. 2005;1039:503–507.PubMedCrossRefGoogle Scholar
  3. 2a.
    Adams HR, Kwan J, Marshall FJ, et al. Neuropsychological symptoms of juvenile-onset batten disease: experience from 2 studies. J Child Neurol. 2007;22:621–627.PubMedCrossRefGoogle Scholar
  4. 3.
    Agamanolis DP, Patre S. Glycone accumulation in the central nervous system in the cerebral-pararenal syndrome. J Neurol Sci. 1979;41:325–342.PubMedCrossRefGoogle Scholar
  5. 4.
    Agamanolis DP, Robinson HB, Timmons GD. Cerebral-pararenal syndrome. A report of a case with histochemical and ultrastructural observations. J Neuropathol Exp Neurol. 1976;35:226–246.PubMedCrossRefGoogle Scholar
  6. 5.
    Aisen AM, Martel W, Gabrielson TO, et al. Wilson disease of the brain: MR imaging. Radiology. 1985;157:137–141.PubMedGoogle Scholar
  7. 6.
    Akaboshi S, Ohno K, Takeshita K. Neuroradiological findings in the carbohydrate-deficient glycoprotein syndromes: An overview. J Inherit Metab Dis. 1993;16:813–820.CrossRefGoogle Scholar
  8. 7.
    Alexander A. Progressive fibrinoid degeneration of fibrillary astrocytes associated with mental retardation in a hydrocephalic infant. Brain. 1949;72:373.PubMedCrossRefGoogle Scholar
  9. 8.
    Altarescu G, Hill S, Wiggs E, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s disease. J Pediatr. 2001;138:539–547.PubMedCrossRefGoogle Scholar
  10. 9.
    Alves D, Pires MM, Guimarães A, et al. Four cases of late onset metachromatic leukodystrophy in a family: Clinical, biochemical, and neuropathological studies. J Neurol Neurosurg Psychiatry. 1986;49:1417–1422.PubMedCrossRefGoogle Scholar
  11. 10.
    Andréasoson S, Blennow G, Ehinger B, et al. Full-field electroretinograms in patients with the carbohydrate-deficient glycoprotein syndrome. Am J Ophthalmol. 1991;112:83–86.Google Scholar
  12. 11.
    Arend AO, Leary PM, Rutherford GS. Alexander’s disease: A case report with brain biopsy, ultrasound, CT scan and MRI findings. Clin Neuropathol. 1991;10:122–126.PubMedGoogle Scholar
  13. 12.
    Arpaia E, Dumbrille-Ross A, Maler T, et al. Identification of an altered splice site in Ashkenazi Tay–Sachs disease. Nature. 1988;333:85–86.PubMedCrossRefGoogle Scholar
  14. 13.
    Ashworth JL, Biswas S, Wraith E, et al. Mucopolysaccharidoses and the eye. Surv Ophthalmol. 2006;51:1–17.PubMedCrossRefGoogle Scholar
  15. 14.
    Auré K, de Baulny HO, Leforêt P, et al. Chronic progressive ophthalmoplegia with large-scale MtDNA rearrangement: Can we predict progression? Brain. 2007;130:1516–1524.PubMedCrossRefGoogle Scholar
  16. 15.
    Bachynski BN, Flynn JT, Rodrigues MM, et al. Hyperglycemic acidotic coma and death in Kearns–Sayre syndrome. Ophthalmology. 1986;93:391–396.PubMedGoogle Scholar
  17. 16.
    Baram TZ, Goldman AM, Percy AK. Krabbe disease: Specific MRI and CT findings. Neurology. 1986;36:111–115.PubMedGoogle Scholar
  18. 17.
    Barkovich AJ. Pediatric Neuroimaging. 2nd ed. New York: Raven; 1995:55–105.Google Scholar
  19. 18.
    Barkovich AJ. Magnetic resonance imaging has revolutionized the diagnosis of white matter disorders in children and adults; Myelin mishaps. Ann Neurol. 2006;62:107–108.CrossRefGoogle Scholar
  20. 19.
    Barkovich AJ, Good WV, Koch TK, et al. Mitochondrial disorders: analysis of their clinical and imaging characteristics. AJNR Am J Neuroradiol. 1993;14:1119–1137.PubMedGoogle Scholar
  21. 20.
    Bass NH, Witmer EJ, Dreifuss FE. A pedigree study of metachromatic leukodystrophy: biochemical identification of a carrier state. Neurology. 1970;20:52–62.PubMedGoogle Scholar
  22. 21.
    Bassen FA, Kornzweig AL. Malformation of the erythrocytes in the case of atypical retinitis pigmentosa. Blood. 1950;5:381–387.PubMedGoogle Scholar
  23. 22.
    Bateman JB, Philippart M. Ocular features of the Hagberg-Santavuori syndrome. Am J Ophthalmol. 1986;102:262–271.PubMedCrossRefGoogle Scholar
  24. 23.
    Bateman JB, Philippart M, Isenberg SJ. Ocular features of multiple sulfatase deficiency and a new variant of metachromatic leukodystrophy. J Pediatr Ophthalmol Strabismus. 1984;21:133–140.PubMedGoogle Scholar
  25. 24.
    Battaglia A, Harden A, Pampiglione G, et al. Adrenoleukodystrophy: neurophysiological aspects. J Neurol Neurosurg Psychiatry. 1981;44:781–785.PubMedCrossRefGoogle Scholar
  26. 25.
    Baumann RJ, Markesbery WR. Santavuori disease: Diagnosis by leukocyte ultrastructure. Neurology. 1982;32:1277–1281.PubMedGoogle Scholar
  27. 26.
    Baumeister FA, Auer DP, Hörtnagel K, et al. The eye-of-the-tiger-sign is not a reliable disease marker for Hallervorden-Spatz syndrome. Neuropediatrics. 2005;36:221–222.PubMedCrossRefGoogle Scholar
  28. 27.
    Beaudoin D, Hagenzieker J, Jack R. Neuronal ceroid lipofuscinosis: What are the roles of electron microscopy, DNA and enzyme analysis in diagnosis? J Histotechnol. 2004;27:237–243.Google Scholar
  29. 28.
    Beck M. Papilloedema in association with Hunter’s syndrome. Br J Ophthalmol. 1983;67:174–177.PubMedCrossRefGoogle Scholar
  30. 29.
    Beck M, Cole G. Disc oedema in association with Hunter’s syndrome: Ocular histopathological findings. Br J Ophthalmol. 1984;68:590–594.PubMedCrossRefGoogle Scholar
  31. 30.
    Begeer JH, Haaxma R, Snoek JW, et al. Signs of focal posterior cerebral abnormality in early subacute sclerosing panencephalitis. Ann Neurol. 1986;19:200–202.PubMedCrossRefGoogle Scholar
  32. 31.
    Berger J, Moser H, Forss-Petterr S. Leukodystrophies: Recent developments in genetics, molecular biology, pathogenesis and treatment. Curr Opin Neurol. 2001;14:305–312.PubMedCrossRefGoogle Scholar
  33. 32.
    Berginer VM, Berginer J, Korezyn AD, et al. Magnetic resonance imaging in cerebrotendinous xanthomatosis: A prospective clinical and neuroradiological study. J Neurol Sci. 1994;122:102–108.PubMedCrossRefGoogle Scholar
  34. 33.
    Biancheri R, Zara F, Bruno C, et al. Phenotypic characterization of hypomyelination and congenital cataracts. Ann Neurol. 2007;62:121–127.PubMedCrossRefGoogle Scholar
  35. 34.
    Biousse V, Newman NJ. Neuro-ophthalmology of mitochondrial diseases. Curr Opin Neurol. 2003;16:35–43.PubMedCrossRefGoogle Scholar
  36. 35.
    Blieden LC, Desnick RJ, Carter JB, et al. Cardiac involvement in Sandhoff’s disease: Inborn error of glycosphingolipid metabolism. Am J Cardiol. 1974;34:83–88.PubMedCrossRefGoogle Scholar
  37. 36.
    Boehme DH, Cottrell JC, Leonberg SC, et al. A dominant form of neuronal ceroid-lipofuscinosis. Brain. 1971;94:745–760.PubMedCrossRefGoogle Scholar
  38. 37.
    Bohlega S, Kambouris M, Shahid M, et al. Gaucher disease with oculomotor apraxia and cardiovascular calcification (Gaucher type IIIC). Neurology. 2000;54:261–263.PubMedGoogle Scholar
  39. 38.
    Borzog S, Ramirez-Montealegre D, Chung M, Pearce DA. Juvenile neuronal ceroid lipofuscinosis (JCNL) and the eye. Surv Ophthalmol. 2009;54:463–471.CrossRefGoogle Scholar
  40. 39.
    Bouchet C, Steffann J, Corcos J, et al. Prenatal diagnosis of myopathy, encephalopathy, lactic acidosis, and stroke-like syndrome: Contribution to understanding mitochondrial DNA segregation during human embryofetal development. J Med Genet. 2006;43:788–792.PubMedCrossRefGoogle Scholar
  41. 40.
    Brenner M, Johnson AB, Boespflug-Tanguy O, et al. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander’s disease. Nat Genet. 2001;27:117–120.PubMedCrossRefGoogle Scholar
  42. 41.
    Brismar J, Brismar G, Gascon G, et al. Canavan disease: CT and MR imaging of the brain. Am J Neurol Res. 1990;11:805–810.Google Scholar
  43. 42.
    Brismar J, Gascon GG, von Steyern KV, et al. Subacute sclerosing panencephalitis: Evaluation with CT and MR. AJNR Am J Neuroradiol. 1996;17:761–772.PubMedGoogle Scholar
  44. 43.
    Broadhead DM, Kirk JM, Burt AJ, et al. Full expression of Hunter’s disease in a female with an x-chromosome deletion leading to nonrandom inactivation. Clin Genet. 1986;30:392–398.PubMedCrossRefGoogle Scholar
  45. 44.
    Bronson RT, Lake BD, Cook S, et al. Motor neuron degeneration of mice is a model of neuronal ceroid lipofuscinosis (Batten’s disease). Ann Neurol. 1993;33:381–385.PubMedCrossRefGoogle Scholar
  46. 45.
    Brownstein S, Meagher-Villemure K, Polomeno RC, et al. Optic nerve and globoid leukodystrophy (Krabbe’s disease). Arch Ophthalmol. 1978;96:864–870.PubMedGoogle Scholar
  47. 46.
    Carbone AO, Petrozzi CF. Gaucher’s disease: Case report with stress on eye findings. Henry Ford Hosp Med J. 1968;16:55–60.PubMedGoogle Scholar
  48. 47.
    Carpenter S, Karpati G, Andermann E. Specific involvement of muscle, nerve, and skin in late infantile and juvenile amaurotic idiocy. Neurology. 1972;22:170–186.PubMedGoogle Scholar
  49. 48.
    Carr RE, Siegel IM. Visual Electrodiagnostic Testing: A Practical Guide for the Clinician. Baltimore: Williams & Wilkins; 1982:1–33.Google Scholar
  50. 49.
    Caruso RC, Kaiser-Kupfer MI, Muenzer J, et al. Electroretinographic findings in the mucopolysaccharidoses. Ophthalmology. 1986;93:1612–1616.PubMedGoogle Scholar
  51. 50.
    Case Records of the Massachusetts General Hospital. N Engl J Med. 1998; 1914–1924.Google Scholar
  52. 51.
    Casteels I, Spillers W, Swinnen T, et al. Optic atrophy as the presenting sign in Hallervorden-Spatz syndrome. Neuropediatrics. 1994;25:265–267.PubMedCrossRefGoogle Scholar
  53. 52.
    Cavanagh N, Kendall B. High density on computed tomography in infantile Krabbe’s disease: A case report. Dev Med Child Neurol. 1986;28:799–802.PubMedCrossRefGoogle Scholar
  54. 53.
    Cerezyme information page. Genezyme Corp. Web site. Accessed July 9, 2008, at:
  55. 54.
    Chabria S, Tomasi LG, Wong PW. Ophthalmoplegia and bulbar palsy in variant form of maple syrup urine disease. Ann Neurol. 1979;6:71–72.CrossRefGoogle Scholar
  56. 55.
    Charrow J, Esplin JA, Gribble TJ. Gaucher disease. Recommendations on diagnosis, evaluation, and monitoring. Arch Int Med. 1998;158:1754–1758.CrossRefGoogle Scholar
  57. 56.
    Chase DS, Morris AH, Ballabio A, et al. Genetics of Hunter syndrome: Carrier detection, new mutations, segregation and linkage analysis. Ann Hum Genet. 1986;50:349–360.PubMedCrossRefGoogle Scholar
  58. 57.
    Chen V. Dietary treatment proposed for Canavan’s disease. Lancet Neurol. 2005;4:273.PubMedCrossRefGoogle Scholar
  59. 58.
    Cogan DG, Chu FC, Barranger J, et al. Maculo halo syndrome. Variant of Niemann–Pick disease. Arch Ophthalmol. 1983;101:1698–7000.PubMedGoogle Scholar
  60. 59.
    Cogan DG, Chu FC, Gittinger J, et al. Fundal abnormalities of Gaucher’s disease. Arch Ophthalmol. 1980;98:2202–2203.PubMedGoogle Scholar
  61. 60.
    Cogan DC, Chu FC, Reingold DR, et al. A long-term follow-up of congenital ocular motor apraxia. Neuroophthalmology. 1980;1:145–147.CrossRefGoogle Scholar
  62. 61.
    Cogan DG, Chu FC, Reingold D, et al. Ocular motor signs in some metabolic diseases. Arch Ophthalmol. 1981;99:1802–1808.PubMedGoogle Scholar
  63. 62.
    Cogan DG, Kawabora T. Histochemistry of the retina in Tay–Sachs disease. Arch Ophthalmol. 1959;61:414–423.Google Scholar
  64. 63.
    Cogan DG, Kawabora T, Moser H. Metachromatic leukodystrophy. Ophthalmologica. 1970;80:2–17.CrossRefGoogle Scholar
  65. 64.
    Cogan DG, Rodrigues M, Chu FC, et al. Ocular abnormalities in abetalipoproteinemia: A clinicopathologic correlation. Ophthalmology. 1984;91:991–998.PubMedGoogle Scholar
  66. 65.
    Collins J. The International Batten Disease Consortium. Isolation of a novel gene underlying Batten disease. CLN3. Cell. 1995;82:949–957.CrossRefGoogle Scholar
  67. 66.
    Collins J, Holder GE, Herbert H, et al. Batten disease: Features to facilitate early diagnosis. Br J Ophthalmol. 2006;90:1119–1124.PubMedCrossRefGoogle Scholar
  68. 67.
    Collins ML, Traboulsi EI, Maumenee IH. Optic nerve head swelling and optic atrophy in the systemic mucopolysaccharidoses. Ophthalmology. 1990;97:1445–1449.PubMedGoogle Scholar
  69. 68.
    Connell P, McCreery K, Doyle A, et al. Central corneal thickness and its relationship to intraocular pressure in mucopolysaccharidoses-1 following bone marrow transplantation. J AAPOS. 2008;12:7010.Google Scholar
  70. 69.
    Cooper J. Progress toward understanding the neurobiology of Batten disease or neuronal ceroid lipofuscinosis. Curr Opin Neurol. 2003;16:121–128.PubMedCrossRefGoogle Scholar
  71. 70.
    Copenhaver RM, Goodman G. The electroretinogram in infantile, late infantile, and juvenile amaurotic familial idiocy. Arch Ophthalmol. 1960;63:559–566.PubMedGoogle Scholar
  72. 71.
    Cox CS, Dubey P, Raymond GV, et al. Cognitive evaluation of neurologically-asymptomatic boys with x-linked adrenal leukodystrophy. Arch Neurol. 2006;63:69–73.PubMedCrossRefGoogle Scholar
  73. 72.
    Crisi G, Ferrari G, Merelli E, et al. MRI in a case of Kearns–Sayre syndrome confirmed by molecular analysis. Neuroradiology. 1994;36:37–38.PubMedCrossRefGoogle Scholar
  74. 73.
    Cruysberg JR, Wevers RA, van Engelen BG, et al. Ocular and systemic manifestations of cerebrotendinous xanthomatosis. Am J Ophthalmol. 1995;120:597–604.PubMedGoogle Scholar
  75. 74.
    Dabbagh O, Swaiman KF. Cockayne syndrome: MRI correlates of hypomyelination. Pediatr Neurol. 1988;4:113–116.PubMedCrossRefGoogle Scholar
  76. 75.
    Dangel ME, Tsou BH. Retinal involvement in Morquio’s syndrome (MPS IV). Ann Ophthalmol. 1985;17:349–354.PubMedGoogle Scholar
  77. 76.
    Darin N, Oldfors A, Moslemi A-R, et al. The incidence of mitochondrial encephalomyopathies in childhood: Clinical features and morphological, biochemical, and DNA abnormalities. Ann Neurol. 2001;49:377–383.PubMedCrossRefGoogle Scholar
  78. 77.
    Daroff R. CPEO in Kearns–Sayre syndrome: An update. North American Neuro-Ophthalmology Society Meeting. Cancun, Mexico; 1989.Google Scholar
  79. 78.
    Dawson JR Jr. Cellular inclusions in cerebral lesions of lethargic encephalitis. Am J Pathol. 1933;9:7–16.PubMedGoogle Scholar
  80. 79.
    Debray FG, Lambert M, Chevalier I, et al. Long-term outcome and clinical spectrum of 73 pediatric patients with mitochondrial diseases. Pediatrics. 2007;119:722–733.PubMedCrossRefGoogle Scholar
  81. 80.
    Demaerel P, Kendall BE, Kingsley D. Cranial CT and MRI in diseases with DNA repair defects. Neuroradiology. 1992;34:117–121.PubMedCrossRefGoogle Scholar
  82. 81.
    Demange P, Gia HP, Kalifa G, et al. MR of Kearns–Sayre syndrome. AJNR Am J Neuroradiol. 1989;10(Suppl):S91.PubMedGoogle Scholar
  83. 82.
    Deprez M, D’Houghe M, Misson JP, et al. Infantile and juvenile presentations of Alexander’s disease: A report of two cases. Acta Neurol Scand. 1999;99:158–165.PubMedCrossRefGoogle Scholar
  84. 83.
    Detre JA, Wang ZY, Bogdan AR, et al. Regional variation in brain lactate in Leigh syndrome by localized 1H magnetic resonance spectroscopy. Ann Neurol. 1991;29:218–221.PubMedCrossRefGoogle Scholar
  85. 84.
    Deutsch JA, Asbell PA. Sialidosis and galactosialidosis. In: Gold DH, Weingeist TA, eds. The Eye in Systemic Disease. Philadelphia: J.B. Lippincott; 1990:376–377.Google Scholar
  86. 85.
    Dickinson JP, Holton JB, Lewis GM, et al. Maple syrup urine disease: Four years’ experience with dietary treatment of a case. Acta Pediatr Scand. 1969;58:341–351.CrossRefGoogle Scholar
  87. 86.
    DiMauro S, Bonilla E. Mitochondrial encephalomyopathies. In: Rosenberg RN, Pruisiner SB, DiMauro S, et al., eds. The Molecular and Genetic Basis of Neurological Disease. Boston: Butterworth Heinemann; 1997:201–235.Google Scholar
  88. 87.
    Dinda AK, Sarkar C, Roy S. Rosenthal fibers: an immunohistochemical, ultrastructural and immunoelectron microscopic study. Acta Neuropathol. 1990;79:456–460.PubMedCrossRefGoogle Scholar
  89. 88.
    Dollfus H, Porto F, Caussade P, et al. Ocular manifestations in the inherited DNA repair disorders. Surv Ophthalmol. 2003;48:107–122.PubMedCrossRefGoogle Scholar
  90. 89.
    Dooling EC, Schoene WC, Richardson EP Jr. Hallervorden-Spatz syndrome. Arch Neurol. 1974;30:70–83.PubMedGoogle Scholar
  91. 90.
    Duker JS, Belmont J, Bosley TM. Angioid streaks associated with abetalipoproteinemia. Case Report. Arch Ophthalmol. 1987;105:1173–1174.PubMedGoogle Scholar
  92. 91.
    Dyken PR. Subacute sclerosing panencephalitis. Current status. Neurol Clin. 1985;3:179–196.PubMedGoogle Scholar
  93. 92.
    Egan RA, Weleber RG, Hogarth P, et al. Neuro-Ophthalmologic and electroretinographic findings in Pantothenate Kinase-Associated Neurodegeneration (formerly Hallervorden-Spatz syndrome). Am J Ophthalmol. 2005;140:267–274.PubMedCrossRefGoogle Scholar
  94. 93.
    Ek J, Kase BF, Reith A, et al. Peroxisomal dysfunction in a boy with neurologic symptoms and amaurosis (Leber disease): Clinical and biochemical findings similar to those observed in Zellweger syndrome. J Pediatr. 1986;108:19–24.PubMedCrossRefGoogle Scholar
  95. 94.
    Elsås T, Rinck PA, Isaksen C, et al. Cerebral nuclear magnetic resonance (MRI) in Kearns syndrome. Acta Ophthalmol (Copenh). 1988;66:469–473.CrossRefGoogle Scholar
  96. 95.
    Emery JM, Green WR, Wyllie RG, et al. GM1-gangliosidosis. Ocular and pathological manifestations. Arch Ophthalmol. 1971;85:177–187.PubMedGoogle Scholar
  97. 96.
    Erikson A. Gaucher disease-Norrbottnian Type III. Acta Paediatr Scand Suppl. 1986;326:1–42.PubMedCrossRefGoogle Scholar
  98. 97.
    Fang W, Huang CC, Lee CC, et al. Ophthalmologic manifestation in MELAS syndrome. Arch Neurol. 1993;50:977–980.PubMedGoogle Scholar
  99. 98.
    Farley TJ, Ketonen LM, Bodensteiner JB, et al. Serial MRI and CT findings in infantile Krabbe disease. Pediatr Neurol. 1992;8:455–458.PubMedCrossRefGoogle Scholar
  100. 99.
    Farrell K, Chuang S, Becker LE. Computed tomography in Alexander’s disease. Ann Neurol. 1984;15:605–607.PubMedCrossRefGoogle Scholar
  101. 100.
    Farrell DF, MacMartin MP, Clark AF. Multiple molecular forms of arylsulfatase A in different forms of metachromatic leukodystrophy (MLD). Neurology. 1979;29:16–20.PubMedGoogle Scholar
  102. 101.
    Feanny SJ, Chuang SH, Becker LE, et al. Intracerebral paraventricular hyper densities: A new CT sign in Krabbe globoid cell leukodystrophy. J Inherit Metab Dis. 1987;10:24–27.PubMedCrossRefGoogle Scholar
  103. 102.
    Feigin I, Pena CE, Budzilovich G. The infantile spongy degenerations. Neurology. 1968;18:153–166.PubMedGoogle Scholar
  104. 103.
    Feliciani M, Curatolo P. Early clinical and imaging (high-field MRI) diagnosis of Hallervorden-Spatz disease. Neuroradiology. 1994;36:247–248.PubMedCrossRefGoogle Scholar
  105. 104.
    Fenichel GM. Clinical Pediatric Neurology: A Symptom and Sign Approach. 2nd ed. Philadelphia: W.B. Saunders; 1993.Google Scholar
  106. 105.
    Fettes I, Killinger D, Volpe R. Adrenoleukodystrophy: Report of a familial case. Clin Endocrinol. 1979;11:151–160.CrossRefGoogle Scholar
  107. 106.
    Fink JK, Filling-Katz MR, Sokol J, et al. Clinical spectrum of Niemann–Pick disease type C. Neurology. 1989;39:1040–1049.PubMedGoogle Scholar
  108. 107.
    Fishman MA. Disorders primarily of white matter. In: Swaiman KF, ed. Pediatric Neurology, Principles and Practice, vol. 2. St. Louis, MO: C.V. Mosby Co; 1994:999–1017.Google Scholar
  109. 108.
    Fitzgibbon E. Eye movements in Niemann Pick C disease. Proceedings of the North American Neuro-Ophthalmology Society. Orlando, FL, March 8-13, 2008.Google Scholar
  110. 109.
    Fiumara A, Barone R, Buttitta P, et al. Carbohydrate deficient glycoprotein syndrome type 1a: Ophthalmologic aspects in four Sicilian patients. Br J Ophthalmol. 1994;78:845–846.PubMedCrossRefGoogle Scholar
  111. 110.
    Folz SJ, Trobe JD. The peroxisome and the eye. Surv Ophthalmol. 1991;35:353–368.PubMedCrossRefGoogle Scholar
  112. 111.
    Font RL, Jenis EH, Tuck KD. Measles maculopathy associated with subacute sclerosing panencephalitis: Immunofluorescent and immuno-ultrastructural studies. Arch Pathol. 1973;96:168–174.PubMedGoogle Scholar
  113. 112.
    Francke U. The human gene for beta glucuronidase is on chromosome 7. Am J Hum Genet. 1976;28:357–362.PubMedGoogle Scholar
  114. 113.
    Fuijkschot J, Cruysberg JRM, Willemsen MA, et al. Subclinical changes in the juvenile crystalline macular dystrophy in Sjögren-Larsson syndrome detected by optical coherence tomography. Ophthalmology. 2008;115:870–875.PubMedCrossRefGoogle Scholar
  115. 114.
    Gardner-Thorpe C, Kocen RS. Subacute sclerosing panencephalitis presenting as transient homonymous hemianopia. J Neurol Neurosurg Psychiatry. 1983;46:186–187.PubMedCrossRefGoogle Scholar
  116. 115.
    Gass J, Donald M, eds. Inflammatory diseases of the retina and choroid. In: Stereoscopic Atlas of Macular Diseases. Diagnosis and Treatment, vol. 2. St. Louis, MO: C.V. Mosby; 1987:455–549.Google Scholar
  117. 116.
    Gass J, Donald M, eds. Heredodystrophic disorders affecting the pigment epithelium and retina. In: Stereoscopic Atlas of Macular Diseases. Diagnosis and Treatment, vol. 2. St. Louis, MO: C.V. Mosby; 1987:312.Google Scholar
  118. 117.
    Gass J, Donald M, eds. Heredodystrophic disorders affecting the pigment epithelium and retina. In: Stereoscopic Atlas of Macular Diseases. Diagnosis and Treatment, vol. 2. St. Louis, MO: C.V. Mosby; 1987:316.Google Scholar
  119. 118.
    Gass J, Donald M, eds. Heredodystrophic disorders affecting the pigment epithelium and retina. In: Stereoscopic Atlas of Macular Diseases. Diagnosis and Treatment, vol. 2. St. Louis, MO: C.V. Mosby; 1987:310.Google Scholar
  120. 119.
    Genetics Home Reference: Your Guide to Understanding Genetic Conditions. Lister Hill National Center for Biomedical Communications, National Institutes of Health. Accessed July 9, 2008, at:
  121. 120.
    Germain DP. Gaucher disease: A paradigm for interventional genetics. Clin Genet. 2004;65:77–86.PubMedCrossRefGoogle Scholar
  122. 121.
    Gerth C, Morel CF, Feigenbaum A, et al. Ocular phenotype in patients with methylmalonic aciduria and homocystinuria, cobalamin C type. J AAPOS. 2008;12:591–596.PubMedCrossRefGoogle Scholar
  123. 122.
    Giagheddu M, Tamburini G, Piga M, et al. Comparison of MRI, EEG, Eps and ECD-SPECT in Wilson’s disease. Acta Neurol Scand. 2001;3:71–81.CrossRefGoogle Scholar
  124. 123.
    Gills JP, Hobson R, Hanley WB, et al. Electroretinography and fundus oculi findings in Hurler’s disease and allied mucopolysaccharidoses. Arch Ophthalmol. 1965;74:596–603.PubMedGoogle Scholar
  125. 124.
    Godel V, Blumenthal M, Goldman B, et al. Visual functions in Tay–Sachs disease patients following enzyme replacement therapy. Metab Ophthalmol. 1978;2:27–32.Google Scholar
  126. 125.
    Goebel H. Symposium: The neuronal ceroid-lipofuscinoses (NCL)-a group of lysosomal disorders come of age. Introduction. Brain Pathol. 2004;14:59–60.CrossRefGoogle Scholar
  127. 126.
    Goebel HH, Bode G, Caesar R, et al. Bulbar palsy with Rosenthal fiber formation in the medulla of a 15-year-old girl. Localized form of Alexander’s disease? Neuropediatrics. 1981;12:382–391.PubMedCrossRefGoogle Scholar
  128. 127.
    Goebel H, Wisniewski K. Symposium: The neuronal ceroid-lipofuscinoses (NCL): A group of lysosomal storage diseases come of age. Current state of clinical and morphologicial features in human NCL. Brain Pathol. 2004;14:61–69.PubMedCrossRefGoogle Scholar
  129. 128.
    Goldberg MF, Cotlier E, Fischenscher LG, et al. Macular cherry-red spot, corneal clouding, and betagalactosidase deficiency. Arch Int Med. 1971;128:387.CrossRefGoogle Scholar
  130. 129.
    Goldfischer S, Collins J, Rapin I, et al. Peroxisomal defects in neonatal-onset and X-linked adrenoleukodystrophies. Science. 1985;227:67–70.PubMedCrossRefGoogle Scholar
  131. 130.
    Good WV, Crain LS, Quint RD, et al. Overlooking: A sign of bilateral central scotomata in children. Dev Med Child Neurol. 1992;34:69–73.PubMedCrossRefGoogle Scholar
  132. 131.
    Goto Y, Horai S, Matsuoka T, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes [MELAS]: A correlative study of the clinical features in mitochondrial DNA mutation. Neurology. 1992;42:545–550.PubMedGoogle Scholar
  133. 132.
    Grafe M, Thomas C, Schneider J, et al. Infantile Gaucher’s disease: A case with neuronal storage. Ann Neurol. 1988;23:300–303.PubMedCrossRefGoogle Scholar
  134. 133.
    Green SH, Wirtschafter JD. Ophthalmoscopic findings in subacute sclerosing panencephalitis. Br J Ophthalmol. 1973;57:780–787.PubMedCrossRefGoogle Scholar
  135. 134.
    Gropman AL. The neurological presentations of childhood and adult mitochondrial disease: Established syndromes and phenotypic variations. Mitochondrion. 2004;4(5-6):503–520.PubMedCrossRefGoogle Scholar
  136. 135.
    Gullerman RP. The eye-of-the-tiger sign. Radiology. 2000;2127:895–896.Google Scholar
  137. 136.
    Gullingsrud EO, Krivit W, Summers CG. Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow up. Ophthalmology. 1998;105:1099–1105.PubMedCrossRefGoogle Scholar
  138. 137.
    Hall CW, Liebars I, Dinatale P, et al. Enzymatic diagnosis of the genetic leuco-polysaccharide storage disorders. Methods Enzymol. 1978;50:439–456.PubMedCrossRefGoogle Scholar
  139. 138.
    Hallervorden J. Uber eine familiare Erkrankung im extrapyramidalen System. Dtsch Z Nervenheilk. 1924;81:204–210.CrossRefGoogle Scholar
  140. 139.
    Hallervorden J, Spatz H. Eigenartige Erkrankung im extrapyramidalen System mit besonderer Beteiligung des Globus Pallidus und der Substantia nigra. Z Ges Neurol Psychiatr. 1922;79:254–302.CrossRefGoogle Scholar
  141. 140.
    Hammans SR, Sweeney MG, Brockington M, et al. The mitochondrial DNA transfer RNA-LysA→G(8344) mutation and the syndrome of myoclonic epilepsy with ragged-red fibers (MERRF). Relationship of clinical phenotype to proportion of mutant mitochondrial DNA. Brain. 1991;116:617–632.CrossRefGoogle Scholar
  142. 141.
    Harcourt B, Ashton N. Ultrastructure of the optic nerve in Krabbe’s leukodystrophy. Br J Ophthalmol. 1973;57:885–891.PubMedCrossRefGoogle Scholar
  143. 142.
    Harden A, Adams GG, Taylor DS. The electroretinogram. Arch Dis Child. 1989;64:1080–1087.PubMedCrossRefGoogle Scholar
  144. 143.
    Harris CM, Taylor DSI, Vellodi A. Ocular motor abnormalities in Gaucher disease. Neuropediatrics. 1999;30:289–293.PubMedCrossRefGoogle Scholar
  145. 144.
    Hayflick SJ, Penzien JM, Michi W, et al. Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr Neurol. 2001;25:166–169.PubMedCrossRefGoogle Scholar
  146. 144a.
    Henneke M, Combes P, Diekmann S, et al: GJA12 mutations are a rare cause of Pelizaeus–Merzbacher-like disease. Neurology 2008;70:748–754.Google Scholar
  147. 145.
    Henning KA, Li L, Iyer N, et al. The Ocular manifestations of the inherited DNA repair disorders. Surv Ophthalmol. 2003;48:107–122.CrossRefGoogle Scholar
  148. 146.
    Herndon RM. Is Alexander’s disease a nosologic entity or a common pathologic pattern of diverse etiology? J Child Neurol. 1999;14:275–276.PubMedCrossRefGoogle Scholar
  149. 147.
    Herndon RM, Rubinstein LJ, Freeman JM, et al. Light and electronic observations on Rosenthal fibers in Alexander’s disease and multiple sclerosis. J Neuropathol Exp Neurol. 1970;29:524–551.PubMedCrossRefGoogle Scholar
  150. 148.
    Heroman JW, Rychwalski P, Barr CC. Cherry red spot in sialidosis (mucolipidosis type 1). Arch Ophthalmol. 2008;126:270–271.PubMedCrossRefGoogle Scholar
  151. 149.
    Hiatt RL, Grizzard HT, McNeer P, et al. Ophthalmologic manifestations of subacute sclerosing panencephalitis. Trans Am Acad Ophthalmol Otolaryngol. 1971;75:344–350.PubMedGoogle Scholar
  152. 150.
    Higgins CF. ABC transporters: From microorganisms to man. Annu Rev Cell Biol. 1992;8:67–113.PubMedCrossRefGoogle Scholar
  153. 151.
    Higgins JJ, Patterson MC, Dambrosia JM, et al. A clinical staging classification for type C Niemann–Pick disease. Neurology. 1992;42:2286–2290.PubMedGoogle Scholar
  154. 152.
    Hirano M, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes [MELAS]: Current concepts. J Child Neurol. 1994;9:4–13.PubMedCrossRefGoogle Scholar
  155. 153.
    Hittner HM, Ketzer FL, Mehta RS. Zellweger syndrome: Lenticular opacities indicating carrier status and lens abnormalities characteristic of homozygotes. Arch Ophthalmol. 1981;99:1977–1982.PubMedGoogle Scholar
  156. 154.
    Hofman IKA, Santavouri P, Gottlob I, et al. The Neuronal Ceroid Lipofuscinosis (Batten Disease). Amsterdam, the Netherlands: IOS Press; 1999.Google Scholar
  157. 155.
    Hokezu Y, Kuriyama M, Kubota R, et al. Cerebrotendinous xanthomatosis: Cranial CT and MRI studies in eight patients. Neuroradiology. 1992;34:308–312.PubMedCrossRefGoogle Scholar
  158. 156.
    Holt IJ, Harding AE, Cooper JM, et al. Mitochondrial myopathies: Clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA. Ann Neurol. 1989;26:699–708.PubMedCrossRefGoogle Scholar
  159. 157.
    Honda Y, Sudo M. Electroretinogram and visually evoked cortical potential in Tay–Sachs disease: A report of two cases. J Pediatr Ophthalmol. 1976;13:226–229.PubMedGoogle Scholar
  160. 158.
    Hormia M. Diffuse cerebral sclerosis, melanoderma and adrenal insufficiency (adrenoleukodystrophy). Acta Neurol Scand. 1978;58:128–133.PubMedCrossRefGoogle Scholar
  161. 159.
    Hübner CA, Orth U, Senning A, et al. Seventeen novel PLP1 mutations in patients with Pelizaeus–Merzbacher disease. Hum Mutat. 2005;25:321–322.PubMedCrossRefGoogle Scholar
  162. 160.
    Inster-Moati I, Quoc EB, Pless M, et al. Ocular motility in Wilson’s disease: a study on 34 patients. J Neurol Neurosurg Psychiatry. 2007;78:1199–1201.CrossRefGoogle Scholar
  163. 161.
    International Batten Disease Consortium. Isolation of a novel gene underlying batten disease. CLN3. Cell. 1995;82:949–957.CrossRefGoogle Scholar
  164. 162.
    Jaben S, Flynn JT. Neuronal ceroid lipofuscinosis (Batten-Vogt’s disease). In: Neuro-Ophthalmology. 1982:Ch. 27.Google Scholar
  165. 163.
    Jaben SL, Flynn JT, Parker JC. Neuronal ceroid lipofuscinosis. Diagnosis from peripheral blood smear. Ophthalmology. 1983;90:1373–1377.PubMedGoogle Scholar
  166. 164.
    Jacob J, Robertson NJ, Hilton DA, et al. The clinicopathological spectrum of Rosenthal fibre encephalopathy and Alexander’s disease: A case report and review of the literature. J Neurol Neurosurg Psychiatry. 2003;74:807–810.PubMedCrossRefGoogle Scholar
  167. 165.
    Jacobson DM. Angioid streaks associated with abetalipoproteinemia. Arch Ophthalmol. 1987;105:1173–1174.Google Scholar
  168. 166.
    Jaeken J, Artigas J, Barone R, et al. Phosphomannomutase deficiency is the main cause of carbohydrate-deficient glycoprotein syndrome with type 1 isoelectrofocusing pattern of serum sialotransferrins. J Inherit Metab Dis. 1997;44:109–140.Google Scholar
  169. 167.
    Jampel RS, Falls HF. Atypical retinitis pigmentosa, acanthocytosis and herido degenerative neuromuscular disease. Arch Ophthalmol. 1958;59:818–820.Google Scholar
  170. 168.
    Jampel RS, Quaglio ND. Eye movements in Tay–Sach’s disease. Neurology. 1964;14:1013–1019.PubMedGoogle Scholar
  171. 169.
    Janson CG, Assidi M, Francis J, et al. Lithium citrate for Canavan disease. Pediatr Neurol. 2005;33:235–243.PubMedCrossRefGoogle Scholar
  172. 170.
    Johnson AB. Alexander disease. In: Moser HW, ed. Neurodystrophies and Neurolipidosis. Handbook of Clinical Neurology, vol. 66 (revised series 22). Amsterdam: Elsevier; 1996:701–710.Google Scholar
  173. 171.
    Kaback MM, Desnick RJ. Tay–Sachs disease: From clinical description to molecular defect. Adv Genet. 2001;44:1–9.PubMedCrossRefGoogle Scholar
  174. 172.
    Kaback M, Lim-Steele J, Dabholkar D, et al. Tay–Sachs disease - Carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. JAMA. 1993;270:2307–2315.PubMedCrossRefGoogle Scholar
  175. 173.
    Kamata Y, Mashima Y, Yokoyama M, et al. Patient with Kearns–Sayre syndrome exhibiting abnormal magnetic resonance image of the brain. J Neuroophthalmol. 1998;18:284–288.PubMedGoogle Scholar
  176. 174.
    Käsmann-Kellner B, Weindler J, Pfau B, et al. Ocular changes in mucopolysaccharidosis IV A (Morquio A syndrome) and long-term results of perforating keratoplasty. Ophthalmologica. 1999;213:200–205.PubMedCrossRefGoogle Scholar
  177. 175.
    Kaul R, Balamurugan K, Gao GP, et al. Canavan disease: Genomic organization and localization of human ASPA to 17p13-ter: Conservation of the ASPA gene during evolution. Genomics. 1994;21:364–370.PubMedCrossRefGoogle Scholar
  178. 176.
    Kaul RK, Gao GP, Balamurugan K, et al. Human aspartocyclase cDNA and missense mutation in Canavan disease. Nat Genet. 1993;5:118–123.PubMedCrossRefGoogle Scholar
  179. 177.
    Kayden HJ, Traber MG. Absorption, lipoprotein transport, and regulation of plasma concentrations of vitamin E in humans. J Lipid Res. 1993;34:343–358.PubMedGoogle Scholar
  180. 178.
    Keane JR. Lid-opening apraxia in Wilson’s disease. J Clin Neuroophthalmol. 1988;8:31–33.PubMedGoogle Scholar
  181. 179.
    Kendall BE. Disorders of lysosomes, peroxisomes, and mitochondria. Am J Neuroradiol. 1992;13:621–653.PubMedGoogle Scholar
  182. 180.
    Keppler K, Cunniff C. Variable presentation of cytochrome c oxidase deficiency. Am J Dis Child. 1992;146:1349–1352.PubMedGoogle Scholar
  183. 181.
    Kerrison KB, Biousse V, Newman NJ. Retinopathy of NARP syndrome. Arch Ophthalmol. 2000;118:298–299.PubMedGoogle Scholar
  184. 182.
    Kirkham TH, Kamin DF. Slow saccadic eye movements in Wilson’s disease. J Neurol Neurosurg Psychiatry. 1974;37:191–194.PubMedCrossRefGoogle Scholar
  185. 183.
    Kivlin JD, Sanborn GE, Myers GG. The cherry-red spot in Tay–Sachs and other storage diseases. Ann Neurol. 1985;17:356–360.PubMedCrossRefGoogle Scholar
  186. 184.
    Kotagal S, Geller TJ, Wall D, Lastra C. A child with reading impairment and a family history of adrenoleukodystrophy. Semin Pediatr Neurol. 1999;6:233–236.PubMedCrossRefGoogle Scholar
  187. 185.
    Krasnewich D, Gahl WA. Carbohydrate-deficient glycoprotein syndrome. Adv Pediatr. 1997;44:109–140.PubMedGoogle Scholar
  188. 186.
    Lackner KJ, Monge JC, Gregg RE, et al. Analysis of the apolipoprotein B gene and messenger ribonucleic acid in abetalipoproteinemia. J Clin Invest. 1986;78:1707–1712.PubMedCrossRefGoogle Scholar
  189. 187.
    Landers MB III, Klintworth GK. Subacute sclerosing panencephalitis (SSPE). A clinicopathologic study of the retinal lesions. Arch Ophthalmol. 1971;86:156–163.PubMedGoogle Scholar
  190. 188.
    Leavitt JA, Kotagal S. The “cherry red” spot. Pediatr Neurol. 2007;37:74–75.PubMedCrossRefGoogle Scholar
  191. 189.
    Lee C, Dineen TE, Brack M, et al. The mucopolysaccharidoses: Characterization by cranial MR imaging. Am J Neuroradiol. 1993;14:1285–1292.PubMedGoogle Scholar
  192. 190.
    Lee MS, Kim YD, Lyoo CH. Oculogyric crisis as an initial manifestation of Wilson’s disease. Neurology. 1999;52:1714–1715.PubMedGoogle Scholar
  193. 191.
    Lee AG, Olson RJ, Bonthius DJ, Phillips PH. Increasing exotropia and decreasing vision in a school-aged boy. Surv Ophthalmol. 2007;52:672–679.PubMedCrossRefGoogle Scholar
  194. 192.
    Lee AG, Olson RJ, Bonthius DJ, et al. Increasing exotropia and decreasing vision in a school-aged boy. Surv Ophthalmol. 2007;52:672–679.PubMedCrossRefGoogle Scholar
  195. 193.
    Leigh RJ, Zee DS. The Neurology of Eye Movements: Contemporary Neurology Series, vol. 4. 2nd ed. Philadelphia: Oxford University Press; 2006:680.Google Scholar
  196. 194.
    Lennox G, Jones R. Gaze distractibility in Wilson’s disease. Ann Neurol. 1989;25:415–417.PubMedCrossRefGoogle Scholar
  197. 195.
    Leone P, Janson CG, Bilanuk L. Aspartoacylase gene transfer to the central nervous system with therapeutical implications for Canavan disease. Ann Neurol. 2000;48:27–38.PubMedCrossRefGoogle Scholar
  198. 196.
    Levin PS, Green WR, Victor DI, et al. Histopathology of the eye in Cockayne’s syndrome. Arch Ophthalmol. 1983;101:1093–1097.PubMedGoogle Scholar
  199. 197.
    Libert J, Van Hoof F, Toussaint D, et al. Ocular findings in metachromatic leukodystrophy. Arch Ophthalmol. 1979;97:1495–1504.PubMedGoogle Scholar
  200. 198.
    Lowden JA. Evidence for a hybrid hexosaminidase isoenzyme and heterozygotes for Sandhoff disease. Am J Hum Genet. 1979;31:281–289.PubMedGoogle Scholar
  201. 199.
    Lyon G, Adams RD, Kolodny EH. Neurology of Hereditary Metabolic Diseases in Children. 2nd ed. New York: McGraw-Hill; 1996.Google Scholar
  202. 200.
    Lysosomal Storage Disorders: Pharmacological Chaperones and Mechanism of Action. Amicus Therapeutics Web site. Accessed July 9, 2008, at:
  203. 201.
    MacDonald JT, Sher PK. Ophthalmoplegia as a sign of metabolic disease in the newborn. Neurology. 1977;27:971–973.PubMedGoogle Scholar
  204. 202.
    MacFaul R, Cavanagh N, Lake BD, et al. Metachromatic leukodystrophy: Review of 38 cases. Arch Dis Child. 1982;57:168–175.PubMedCrossRefGoogle Scholar
  205. 203.
    Macmillan CJ, Shoubridge EA. Mitochondrial DNA depletion: Prevalence in a pediatric population referred for neurologic evaluation. Pediatr Neurol. 1996;14:203–210.PubMedCrossRefGoogle Scholar
  206. 204.
    Madhavarao CN, Arun P, Moffett JR, et al. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan’s disease. Proc Natl Acad Sci USA. 2005;102:5221–5226.PubMedCrossRefGoogle Scholar
  207. 205.
    Magalhaes AC, Caramelli P, Menezes JR, et al. Wilson’s disease: MRI with clinical correlation. Neuroradiology. 1994;36:97–100.PubMedCrossRefGoogle Scholar
  208. 206.
    Mallery DL, Tanganelli B, Colella S, et al. Molecular analysis of mutations in the CSB (ERCC6) gene in patients with Cockayne syndrome. Am J Hum Genet. 1998;62:77–85.PubMedCrossRefGoogle Scholar
  209. 207.
    Marble M, Voeller KS, May MM. Pelizaeus–Merzbacher syndrome: Neurocognitive function in a family with carrier manifestations. Am J Med Genet. 2007;143A:1442–1447.PubMedCrossRefGoogle Scholar
  210. 208.
    Markesbery WR, Shield LK, Egel RT, et al. Late infantile neuronal ceroid-lipofuscinosis: An ultrastructural study of lymphocyte inclusions. Arch Neurol. 1976;33:630–635.PubMedGoogle Scholar
  211. 209.
    Matalon R, Michals K, Sebesta D, et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet. 1988;29:463–471.PubMedCrossRefGoogle Scholar
  212. 210.
    Matthews PM, Tampieri D, Berkovic SF, et al. Magnetic resonance imaging shows specific abnormalities in the MELAS syndrome. Neurology. 1991;41:1043–1046.PubMedGoogle Scholar
  213. 211.
    McGovern MM, Wasserstein MP, Aron A. Ocular manifestations of Neimann-Pick disease type B. Ophthalmology. 2004;111:1424–1427.PubMedCrossRefGoogle Scholar
  214. 212.
    McGuinness MC, Wei H, Smith KD. Therapeutic developments in peroxisome biogenesis disorders. Expert Opin Investig Drugs. 2000;9:1985–1992.PubMedCrossRefGoogle Scholar
  215. 213.
    Medina L, Chi TL, DeVivo DC. MR findings in patients with subactue necrotizing encephalomyelopathy (Leigh syndrome): Correlation with biochemical defect. AJNR Am J Neuroradiol. 1990;11:379–384.PubMedGoogle Scholar
  216. 214.
    Migeon BR, Moser HW, Moser AB, et al. Adrenoleukodystrophy: Evidence for X linkage, inactivation and selection favoring the mutant allele in heterozygous cells. Proc Natl Acad Sci USA. 1981;78:5066–5070.PubMedCrossRefGoogle Scholar
  217. 215.
    Migita M, Hamada H, Fujimura J, et al. Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy-unsuccessful treatment of the neurologic abnormality in type 2 Gaucher disease. Eur J Pediatr. 2003;162:524–525.PubMedCrossRefGoogle Scholar
  218. 216.
    Mole SE. The neuronal ceroid lipofuscinosis (NCL): A group of lysosomal diseases come of age. Brain Pathol. 2004;14:70–76.PubMedCrossRefGoogle Scholar
  219. 217.
    Moloney JB, Masterson JG. Detection of adrenoleukodystrophy carriers by means of evoked potentials. Lancet. 1982;2:852–853.PubMedCrossRefGoogle Scholar
  220. 218.
    Moossy J. The neuropathology of Cockayne’s syndrome. J Neuropathol Exp Neurol. 1967;26:654–660.PubMedCrossRefGoogle Scholar
  221. 219.
    Morales CT, Shanske S, Tritschler HJ, et al. MtDNA depletion with variable tissue expression: A novel genetic abnormality in mitochondrial disease. Am J Hum Genet. 1991;48:492–501.Google Scholar
  222. 220.
    Morava E, Wosik HN, Sykut-Cegielska J, et al. Ophthalmological abnormalities in children with congenital disorders of glycosylation type 1. Br J Ophthalmol. 2009;93:350–354.PubMedCrossRefGoogle Scholar
  223. 221.
    Moser HW. Adrenoleukodystrophy: Phenotype, genetics, pathogenesis, and therapy. Brain. 1997;120:1485–1508.PubMedCrossRefGoogle Scholar
  224. 222.
    Moser AB, Kreiter N, Bezman L, et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol. 1999;45:100–110.PubMedCrossRefGoogle Scholar
  225. 223.
    Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. Nat Clin Pract Neurol. 2007;3:140–150.PubMedCrossRefGoogle Scholar
  226. 224.
    Moser HW, Raymond GV, Dubey P. Adrenoleukodystrophy: New Approaches to a neurodegenerative disease. JAMA. 2005;294:3131–3134.PubMedCrossRefGoogle Scholar
  227. 225.
    Moser HW, Raymond GV, Lu SE, et al. Follow up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo’s oil. Arch Neurol. 2005;62:1073–1080.PubMedCrossRefGoogle Scholar
  228. 226.
    Moser AE, Singh I, Brown FR III, et al. The cerebrohepatorenal (Zellweger) syndrome. Increased levels and impaired degradation of very-long-chain fatty acids and their use in prenatal diagnosis. N Engl J Med. 1984;319:1141–1146.CrossRefGoogle Scholar
  229. 227.
    Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985;37:1–31.PubMedGoogle Scholar
  230. 228.
    Muller DP. Effect of large oral doses of vitamine E on the neurological sequelae of patients with abetalipoproteinemia. In: Lubin B, Machlin LJ, eds. Vitamin E: Biochemical, Hematological and Clinical Aspects. New York: New York Academy of Sciences; 1992:133–144.Google Scholar
  231. 229.
    Naidu S, Hofmann KJ, Moser HW, et al. Galactosylceramide-beta-galactosidase deficiency in association with cherry red spot. Neuropediatrics. 1988;19:46–48.PubMedCrossRefGoogle Scholar
  232. 230.
    Naidu S, Moser H. Peroxisomal disorders. In: Swaiman KF, ed. Pediatric Neurology. Principles and Practice. 2nd ed. St. Louis, MO: C.V. Mosby; 1994:1357–1383.Google Scholar
  233. 231.
    Nakagawa E, Hirano S, Yamauchi H, et al. Progressive brainstem and white matter lesions in Kearns–Sayre syndrome: A case report. Brain Dev. 1994;16:416–418.PubMedCrossRefGoogle Scholar
  234. 232.
    Nakaya-Onishi M, Suzuki A, Okamoto N, et al. Observations on time course changes of the cherry red spot in a patient with Tay–Sachs disease. Br J Ophthalmol. 2000;2000(84):1320–1321.Google Scholar
  235. 233.
    Nance MA, Berry SA. Cockayne syndrome: Review of 140 cases. Am J Med Genet. 1992;42:167–179.CrossRefGoogle Scholar
  236. 234.
    Naughten ER, Jenkins J, Francis DE, et al. Outcome of maple syrup urine disease. Arch Dis Child. 1982;57:918–921.PubMedCrossRefGoogle Scholar
  237. 235.
    Neville BG, Lake BD, Stephens R, et al. A neurovisceral storage disease with vertical supranuclear ophthalmoplegia and its relationship to Niemann–Pick disease: A report of nine patients. Brain. 1973;96:97–120.PubMedCrossRefGoogle Scholar
  238. 236.
    Ni Q, Johns GS, Manepalli A, et al. Infantile Alexander’s disease: Serial neuroradiologic findings. J Child Neurol. 2002;17:463–466.PubMedCrossRefGoogle Scholar
  239. 237.
    Ortiz R, Newman NJ, Shoffner JM, et al. Variable retinal and neurological manifestations in patients harboring the mtDNA 8993 mutation. Arch Ophthalmol. 1993;111:1525–1530.PubMedGoogle Scholar
  240. 238.
    Ortube MC, Bhola R, Demer JL. Orbital magnetic resonance imaging of extraocular muscles in chronic progressive external ophthalmoplegia: Specific diagnostic findings. J AAPOS. 2006;10:414–418.PubMedCrossRefGoogle Scholar
  241. 239.
    Ozawa M, Nishino I, Horai S, et al. Myoclonus epilepsy associated with ragged-red fibers. A G-to-A mutation at nucleotide pair 8363 in mitochondrial tRNA(lys) in two families. Muscle Nerv. 1997;20:271–278.CrossRefGoogle Scholar
  242. 240.
    Pampiglione G, Harden A. So-called neuronal ceroid lipofuscinosis: Neurophysiological studies in 60 children. J Neurol Neurosurg Psychiatry. 1977;40:323–330.PubMedCrossRefGoogle Scholar
  243. 241.
    Pampiglione G, Privett G, Harden A. Tay–Sachs disease: Neurophysiological studies in 20 children. Dev Med Child Neurol. 1974;16:201–208.PubMedCrossRefGoogle Scholar
  244. 242.
    Patterson MC, Di Bisceglie AM, Higgens JJ, et al. The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Neimann-Pick disease type C. Neurology. 1993;43:61–64.PubMedGoogle Scholar
  245. 243.
    Patterson MC, Horowitz M, Abel RB, et al. Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher’s disease. Neurology. 1993;43:1993–1997.PubMedGoogle Scholar
  246. 244.
    Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann–Pick C disease: A randomised controlled study. Lancet Neurol. 2007;6:765–772.PubMedCrossRefGoogle Scholar
  247. 245.
    Peachey NS, Sokol S, Moskowitz A. Recording the contralateral PERG: Effect of different electrodes. Invest Ophthalmol Vis Sci. 1983;24:1514–1516.PubMedGoogle Scholar
  248. 246.
    Pearce JM. Canavan’s disease. J Neurol Neurosurg Psychiatry. 2004;75:1410.PubMedCrossRefGoogle Scholar
  249. 247.
    Percy AK, Brady RO. Metachromatic leukodystrophy: diagnosis with samples of venous blood. Science. 1968;161:594–595.PubMedCrossRefGoogle Scholar
  250. 248.
    Peters C, Charnas LR, Tan Y, et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood. 2004;104:881–888.PubMedCrossRefGoogle Scholar
  251. 249.
    Pitz S, Ogun O, Bajbouj M, et al. Ocular changes in patients with mucopolysaccharidosis 1 receiving enzyme replacement therapy: A 4-year experience. Arch Ophthalmol. 2007;125:1353–1356.PubMedCrossRefGoogle Scholar
  252. 250.
    Plant GT, Hess RF. The electrophysiological assessment of optic neuritis. In: Hess RF, Plant GT, eds. Optic Neuritis. Cambridge, MA: University Press; 1986:208–214.Google Scholar
  253. 251.
    Poll-The BT, Maillette de Buy Wenniger-Prick LJ, Barth PG, et al. The eye as a window to inborn errors of metabolism. J Inherit Metab Dis. 2003;26:229–244.PubMedCrossRefGoogle Scholar
  254. 252.
    Pontikis CC, Cella CV, Parihar N, et al. Late-onset neurodegeneration in the cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res. 2004;1023:231–242.PubMedCrossRefGoogle Scholar
  255. 253.
    Porter-Grenn L, Silbergleit R, Mehta BA. Hallervorden-Spatz disease with bilateral involvement of globus pallidus and substantia nigra: MR demonstration. J Comput Assist Tomogr. 1993;17:961–963.PubMedCrossRefGoogle Scholar
  256. 254.
    Pridmore CL, Baraitser M, Harding B, et al. Alexander’s disease: Clues to diagnosis. J Child Neurol. 1993;8:134–144.PubMedCrossRefGoogle Scholar
  257. 255.
    Rader DJ, Brewer HB Jr. Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA. 1993;270:865–869.PubMedCrossRefGoogle Scholar
  258. 256.
    Rahman S, Blok RB, Dahl HH, et al. Leigh syndrome: Clinical features and biochemical and DHA abnormalities. Ann Neurol. 1996;39:343–351.PubMedCrossRefGoogle Scholar
  259. 257.
    Raininko R, Santavuori P, Heiskala H, et al. CT findings in neuronal ceroid lipofuscinosis. Neuropediatrics. 1990;21:95–101.PubMedCrossRefGoogle Scholar
  260. 258.
    Rapin I, Weidenheim K, Lindenbaum Y, et al. Cockayne syndrome in adults: Review with clinical and pathological study of a new case. J Child Neurol. 2006;21:991–1006.PubMedCrossRefGoogle Scholar
  261. 259.
    Reichard EA, Ball WS Jr, Bove KE. Alexander disease: A case report and review of the literature. Pediatr Pathol Lab Med. 1996;16:327–343.PubMedCrossRefGoogle Scholar
  262. 260.
    Reider-Grosswasser I, Bornstein N. CT and MRI in late-onset metachromatic leukodystrophy. Acta Neurol Scand. 1987;75:64–69.PubMedCrossRefGoogle Scholar
  263. 261.
    Renaud DL, Kotagal S. Pantothenate-kinase associated neurodegeneration (PKAN) “Eye of the Tiger” sign. Pediatr Neurol. 2007;36:70–71.PubMedCrossRefGoogle Scholar
  264. 262.
    Renteria VG, Ferrans VJ, Roberts WC. The heart in the Hurler syndrome: Gross histologic and ultrastructural observations in five necropsy cases. Am J Cardiol. 1976;38:487–501.PubMedCrossRefGoogle Scholar
  265. 263.
    Resnick JS, Engel WK, Sever JL. Subacute sclerosing panencephalitis. Spontaneous improvement in a patient with elevated measles antibody in blood and spinal fluid. N Engl J Med. 1968;279:126–129.PubMedCrossRefGoogle Scholar
  266. 264.
    Risk WS, Haddad FS, Chemali R. Substantial spontaneous long-term improvement in subacute sclerosing panencephalitis. Six cases from the Middle East and a review of the literature. Arch Neurol. 1978;35:494–502.PubMedGoogle Scholar
  267. 265.
    Robb RM, Watters GV. Ophthalmic manifestations of subacute sclerosing panencephalitis. Arch Ophthalmol. 1970;83:426–435.PubMedGoogle Scholar
  268. 266.
    Robertson WC Jr, Clark DB, Markesbery WR. Review of 38 cases of subacute sclerosing panencephalitis: Effect of amantadine on the natural course of the disease. Ann Neurol. 1980;8:422–425.PubMedCrossRefGoogle Scholar
  269. 267.
    Röttach KG, von Maydell RD, Das VE, et al. Evidence for independent feedback control of horizontal and vertical saccades from Niemann–Pick type C disease. Vision Res. 1997;37:3627–3638.PubMedCrossRefGoogle Scholar
  270. 268.
    Rucker JC, Shapiro BE, Han YH, et al. Neuro-ophthalmology of late-onset Tay–Sachs disease (LOTS). Neurology. 2004;63:1918–1926.PubMedGoogle Scholar
  271. 269.
    Runge P, Muller DP, McAllister J, et al. Oral vitamin E supplements can prevent the retinopathy of abetalipoproteinemia. Br J Ophthalmol. 1986;70:166–173.PubMedCrossRefGoogle Scholar
  272. 270.
    Russo LS Jr, Aron A, Anderson PJ. Alexander’s disease. A report and reappraisal. Neurology. 1976;26:607–614.PubMedGoogle Scholar
  273. 271.
    Salmon JF, Pan EL, Murray AD. Visual loss with dancing extremities and mental disturbances. Surv Ophthalmol. 1991;35:299–306.PubMedCrossRefGoogle Scholar
  274. 272.
    Salt HB, Wolff OH, Lloyd JK, et al. On having no beta-lipoprotein: A syndrome comprising abetalipoprotein, acanthocytosis, and steatorrhoea. Lancet. 1960;2:325–329.PubMedCrossRefGoogle Scholar
  275. 273.
    Santavuori P, Haltia M, Rapola J, et al. Infantile type of so-called neuronal ceroid lipofuscinosis. 1: A clinical study of 15 patients. J Neurol Sci. 1973;18:257–267.PubMedCrossRefGoogle Scholar
  276. 274.
    Santos MJ, Imanaka T, Shio H, et al. Peroxisomal membrane ghosts in Zellweger syndrome - aberrant organelle assembly. Science. 1988;239:1536–1538.PubMedCrossRefGoogle Scholar
  277. 275.
    Schaumberg HH, Powers JM, Raine CS, et al. Adrenoleukodystrophy: A clinical and pathological study of 17 cases. Arch Neurol. 1975;32:577–591.Google Scholar
  278. 276.
    Scheffer IE, Baraitser M, Wilson J, et al. Pelizaeus Merzbacher disease: Classical or connatal? Neuropediatrics. 1991;22:71–78.PubMedCrossRefGoogle Scholar
  279. 277.
    Schutgens RB, Heymans HS, Wanders RJ, et al. Peroxisomal disorders: A newly recognized group of genetic diseases. Eur J Pediatr. 1986;144:430–440.PubMedCrossRefGoogle Scholar
  280. 278.
    Schwartz JF, Kolendrianos ET. Maple syrup urine disease. A review with a report of an additional case. Dev Med Child Neurol. 1969;11:460–470.PubMedCrossRefGoogle Scholar
  281. 279.
    Sedwick LA, Burde RM, Hodges FJ III. Leigh’s subacute necrotizing encephalomyelopathy manifesting as spasmus nutans. Arch Ophthalmol. 1984;102:1046–1048.PubMedGoogle Scholar
  282. 280.
    Seil FJ, Schochet SS, Earle KM. Alexander’s disease in an adult. Report of a case. Arch Neurol. 1968;19:494–502.PubMedGoogle Scholar
  283. 281.
    Seitelberger F. Pelizaeus Merzbacher disease. In: Viken P, Bruyn G, eds. Handbook of Clinical Neurology. Amsterdam: Elsevier; 1970:150–202.Google Scholar
  284. 282.
    Sethi KD, Adams RJ, Loring DW, et al. Hallervorden-Spatz syndrome: Clinical and magnetic resonance imaging correlations. Ann Neurol. 1988;24:692–694.PubMedCrossRefGoogle Scholar
  285. 283.
    Shapira Y, Harel S, Russell A. Mitochondrial encephalomyopathies: A group of neuromuscular disorders with defects in oxidative metabolism. Isr J Med Sci. 1977;13:161–164.PubMedGoogle Scholar
  286. 284.
    Shimomura C, Matsui A, Choh H, et al. Magnetic resonance imaging in Pelizaeus Merzbacher disease. Pediatr Neurol. 1988;4:124–125.PubMedCrossRefGoogle Scholar
  287. 285.
    Shimozawa T, Tsukamoto Y, Suzuki T, et al. A human gene responsible for Zellweger syndrome that affects peroxisomal assembly. Science. 1992;255:1132–1134.PubMedCrossRefGoogle Scholar
  288. 286.
    Singh I, Moser AE, Moser HW, et al. Adrenoleukodystrophy: Impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes. Pediatr Res. 1984;18:286–290.PubMedCrossRefGoogle Scholar
  289. 287.
    Sistermans EA, de Coo RF, de Wijs IJ, et al. Duplication of the proteolipid protein gene is the major cause of Pelizaeus–Merzbacher disease. Neurology. 1998;50:1749–1754.PubMedGoogle Scholar
  290. 288.
    Sjögren T, Larsson T. Oligophrenia in combination with congenital ichthyosis and spastic disorders: A clinical and genetic study. Acta Psychiatr Neurol Scand Suppl. 1957;113:1–112.PubMedGoogle Scholar
  291. 289.
    Sokol RJ. Vitamin E and neurologic deficits. Adv Pediatr. 1990;37:119–148.PubMedGoogle Scholar
  292. 290.
    Solomon D, Winkelman AC, Zee DS, et al. Niemann–Pick type C disease in two affected sisters: Ocular motor recordings and brain-stem neuropathology. Ann NY Acad Sci. 2005;1039:436–445.PubMedCrossRefGoogle Scholar
  293. 291.
    Souillet G, Guffon N, Maire I, et al. Outcome of 27 patients with Hurler’s syndrome tranplanted from either related or unrelated haemaotopoetic stem cell sources. Bone Marrow Transplant. 2003;31:1005–1117.CrossRefGoogle Scholar
  294. 292.
    Spalton DJ, Taylor DS, Sanders MD. Juvenile Batten’s disease: An ophthalmological assessment of 26 patients. Br J Ophthalmol. 1980;64:726–732.PubMedCrossRefGoogle Scholar
  295. 293.
    Stark KL, Gibson JB, Hertle RW, et al. Ocular motor signs in an infant with carbohydrate-deficient glycoprotein syndrome Type 1a. Am J Ophthalmol. 2000;130:533–535.PubMedCrossRefGoogle Scholar
  296. 294.
    Statz A, Boltshauser E, Schinzel A, et al. Computed tomography in Pelizaeus Merzbacher disease. Neuroradiology. 1981;22:103–105.PubMedCrossRefGoogle Scholar
  297. 295.
    Stefanini M, Fawcett H, Botta E, et al. Genetic analysis of twenty two patients with Cockayne syndrome. Hum Genet. 1996;97:418–423.PubMedCrossRefGoogle Scholar
  298. 296.
    Steinberg SJ, Dodt G, Raymond GV, et al. Peroxisome biogenesis disorders. Biochim Biophys Acta. 2006;1763:1733–1748.PubMedCrossRefGoogle Scholar
  299. 297.
    Stem Cell Information. National Institutes of Health Web site. Accessed July 9, 2008, at:
  300. 298.
    Stevenson RE, Schroer RJ, Schwartz CE. Pelizaeus–Merzbacher Syndrome. X-linked Mental Retardation. New York: Oxford University Press; 2000:266–268.Google Scholar
  301. 299.
    Stockler S, Millner M, Molzer B, et al. Multiple sclerosis-like syndrome in a woman heterozygous for adrenoleukodystrophy. Eur Neurol. 1993;33:390–392.PubMedCrossRefGoogle Scholar
  302. 300.
    Stone DL, Tayebi N, Orvisky E, et al. Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum Mutat. 2000;15:181–188.PubMedCrossRefGoogle Scholar
  303. 301.
    Summers CG, Purple RL. Krivit WL Ocular changes in the mucopolysaccharidoses post bone marrow transplantation. A preliminary report. Ophthalmology. 1989;96:977–984.PubMedGoogle Scholar
  304. 302.
    Surendran S, Matalon KM, Tyring SK, et al. Molecular basis of Canavan’s disease: From human to mouse. J Child Neurol. 2003;18:604–610.PubMedCrossRefGoogle Scholar
  305. 303.
    Suzuki K. Biochemical pathogenesis of genetic leukodystrophies: comparison of metachromatic leukodystrophy and globoid cell leukodystrophy (Krabbe’s disease). Neuropediatrics. 1984;15:32–36.PubMedCrossRefGoogle Scholar
  306. 304.
    Svennerholm L. The gangliosides. J Lipid Res. 1964;5:145–155.PubMedGoogle Scholar
  307. 305.
    Swaiman KF. Hallervorden-Spatz syndrome in brain iron metabolism. Arch Neurol. 1991;48:1285–1293.PubMedGoogle Scholar
  308. 306.
    Swaiman KF. Lysosomal diseases. In: Swaiman KF, ed. Pediatric Neurology, Principles and Practice, vol. 11. 2nd ed. St. Louis, MO: C.V. Mosby; 1994:1275–1334.Google Scholar
  309. 307.
    Swaiman KF. Hallervorden-Spatz syndrome. Pediatr Neurol. 2001;25:102–108.PubMedCrossRefGoogle Scholar
  310. 308.
    Swaiman KF, Smith SA, Trock GL, et al. Sea-blue histiocytes, lymphocytic cytosomes, and 59Fe: Studies in Hallervorden-Spatz syndrome. Neurology. 1983;33:301–305.PubMedGoogle Scholar
  311. 309.
    Tarugi P, Averna M, Di Leo E, et al. Molecular diagnosis of hypobetalipoproteinemia: An ENID review. Atherosclerosis. 2007;195:e19-e27.PubMedCrossRefGoogle Scholar
  312. 310.
    Taylor D. Ophthalmological features of some human hereditary disorders with demyelination. Bull Soc Belge Ophthalmol. 1983;208:405–413.Google Scholar
  313. 311.
    Taylor D. Neurometabolic disease. Pediatric Ophthalmology. London, Edinburgh, Melbourne: Blackwell; 1990:525–544.Google Scholar
  314. 312.
    Traboulsi EI, Maumenee IH. Ophthalmologic manifestations of X-linked childhood adrenoleukodystrophy. Ophthalmology. 1987;94:47–52.PubMedGoogle Scholar
  315. 313.
    Tripp JH, Lake BD, Young E, et al. Juvenile Gaucher’s disease with horizontal gaze palsy in three siblings. J Neurol Neurosurg Psychiatry. 1977;40:470–478.PubMedCrossRefGoogle Scholar
  316. 314.
    Trobe JD, Sharpe JA, Hirsh DK, et al. Nystagmus of Pelizaeus–Merzbacher disease: A magnetic search-coil study. Arch Neurol. 1991;48:87–91.PubMedGoogle Scholar
  317. 315.
    Troelstra C, Landsvater RM, Weigant J, et al. Localization of the nucleotide excision repair gene ERCC6 to human chromosome 10q11-q21. Genomics. 1992;12:745–749.PubMedCrossRefGoogle Scholar
  318. 316.
    Troelstra C, van Gool A, deWit J, et al. ERCC6, a member of a sub-family of putative helicases, is involved in Cockayne’s syndrome and preferential repair of active genes. Cell. 1992;71:939–953.PubMedCrossRefGoogle Scholar
  319. 317.
    Tsina EK, Marsden DL, Hansen RM, et al. Maculopathy and retinal degeneration in cobalamin c Methymalonic aciduria and homocystinuria. Arch Ophthalmol. 2005;123:1143–1145.PubMedCrossRefGoogle Scholar
  320. 318.
    Tulinius MH, Holme E, Kristiansson B, et al. Mitochondrial encephalomyelopathies in childhood. I. biochemical and morphologic investigations. J Pediatr. 1991;119:242–250.PubMedCrossRefGoogle Scholar
  321. 319.
    Tulinius MH, Holme E, Kristiansson B, et al. Mitochondrial encephalomyopathies in childhood. II. Clinical manifestations and syndromes. J Pediatr. 1991;119:251–259.PubMedCrossRefGoogle Scholar
  322. 320.
    Valavanis A, Friede RL, Schubiger O, et al. Computed tomography in neuronal ceroid lipofuscinosis. Neuroradiology. 1980;19:35–38.PubMedGoogle Scholar
  323. 321.
    van der Knaap MS, Barth PG, Gabreëls FJ, et al. A new leukoencephalopathy with vanishing white matter. Neurology. 1997;48:845–855.PubMedGoogle Scholar
  324. 322.
    van der Knaap MS, Valk J. GM2 Gangliosidosis. In: van der Knaap MS, Valk J, eds. Magnetic Resonance of Myelination and Myelin Disorders. 3rd ed. Berlin: Springer; 2005:103–111.Google Scholar
  325. 323.
    van der Knaap MS, Valk J, de Neeling N, et al. Pattern recognition in magnetic resonance imaging of white matter disorders in children and young adults. Neuroradiology. 1991;33:478–493.PubMedCrossRefGoogle Scholar
  326. 324.
    van der Knapp MS, Barth PG, Stroink H, et al. Leukoencephalopathy with swelling and a discrepantly mild clinical course in eight children. Ann Neurol. 1995;37:324–334.CrossRefGoogle Scholar
  327. 325.
    van der Knapp M, Breiter S, Naidu S, et al. Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach. Radiology. 1999;213:121–133.Google Scholar
  328. 326.
    van der Knapp MS, Kamphorst W, Barth PG, et al. Phenotypic variation in leukoencephalopathy with vanishing white matter. Neurology. 1998;51:540–547.Google Scholar
  329. 327.
    van der Knapp MS, Valk J. The reflection of histology in MR imaging of Pelizaeus–Merzbacher disease. Am J Neuroradiol. 1989;10:99–103.Google Scholar
  330. 328.
    van der Knapp MS, Valk J. The MR spectrum of peroxisomal disorders. Neuroradiology. 1991;33:30–37.CrossRefGoogle Scholar
  331. 329.
    van der Voorn JP, Pouwels PJ, Hart AA, et al. Childhood white matter disorders: quantitative MR imaging and spectroscopy. Radiology. 2006;241:510–517.PubMedCrossRefGoogle Scholar
  332. 330.
    van Heijst AFJ, Verrips A, Wevers RA, et al. Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr. 1998;157:313–316.PubMedCrossRefGoogle Scholar
  333. 331.
    van Heijst AF, Wevers RA, Tangerman A, et al. Chronic diarrhea as a dominating symptom in two children with cerebrotendinous xanthomatosis. Acta Pediatr. 1996;85:932–936.CrossRefGoogle Scholar
  334. 332.
    Vellodi A, Young EP, Cooper JE, et al. Bone marrow transplantation for mucopolysaccharidoses type I: Experience of two British centres. Arch Dis Child. 1997;76:92–99.PubMedCrossRefGoogle Scholar
  335. 333.
    Verma NP, Hart ZH, Nigro M. Electrophysiologic studies in neonatal adrenoleukodystrophy. Electroencephalogr Clin Neurophysiol. 1985;60:7–15.PubMedCrossRefGoogle Scholar
  336. 334.
    Vilarhino L, Hattori Y, Goto Y-I, et al. Point mutations in mitochondrial tRNA genes: Sequence analysis of chronic progressive external ophthalmoplegia (CPEO). J Neurol Sci. 1994;125:50–55.CrossRefGoogle Scholar
  337. 335.
    Vilarinho L, Santorelli FM, Cardoso ML, et al. Mitochondrial DNA analysis in ocular myopathy. Observations in 29 Portuguese patients. Eur Neurol. 1998;39:148–153.PubMedCrossRefGoogle Scholar
  338. 336.
    Vilarinho L, Tomé FM, Fardeau M. Ocular myopathies. In: Engle AG, Banker BQ, eds. Myology. New York: McGraw-Hill; 1986:1327–1347.Google Scholar
  339. 337.
    Vincent I, Bu B, Erickson R. Understanding Niemann–Pick C disease: A fat problem. Curr Opin Neurol. 2003;16:155–161.PubMedCrossRefGoogle Scholar
  340. 338.
    Vivian AJ, Harris CM, Kriss A, et al. Oculomotor signs in infantile Gaucher disease. Neuroophthalmology. 1993;13:151–155.CrossRefGoogle Scholar
  341. 339.
    Vu TH, Sciacco M, Tanji K, et al. Clinical manifestations of mitochondrial DNA depletion. Neurology. 1998;50:1783–1790.PubMedGoogle Scholar
  342. 340.
    Wallace D. Mitochondrial genetics: A paradigm for aging and degenerative diseases? Science. 1992;256:628–632.PubMedCrossRefGoogle Scholar
  343. 341.
    Walls TJ, Jones RA, Cartlidge N, et al. Alexander’s disease with Rosenthal fibre formation in an adult. J Neurol Neurosurg Psychiatry. 1984;47:399–403.PubMedCrossRefGoogle Scholar
  344. 342.
    Warner TT, Hammans SR. Practical Neurogenetics. Philadelphia: Elsevier; 2009.Google Scholar
  345. 343.
    Watanabe K, Mukawa A, Muto K, et al. Tay–Sachs disease with conspicuous cranial computerized tomographic appearances. Acta Pathol Jpn. 1985;35:1521–1532.PubMedGoogle Scholar
  346. 344.
    Wei H, Kemp S, McGuinness MC, et al. Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Ann Neurol. 2000;47:286–296.PubMedCrossRefGoogle Scholar
  347. 345.
    Weimer JM, Custer AW, Benedict JW, et al. Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiol Dis. 2006;22:284–293.PubMedCrossRefGoogle Scholar
  348. 346.
    Weismann U, Neufeld EF. Scheie and Hurler syndromes: Apparent identity of the biochemical defect. Science. 1970;169:72–74.CrossRefGoogle Scholar
  349. 347.
    Weller S, Rosewich H, Gärtner J. Cerebral MRI as a valuable diagnostic tool in Zellweger spectrum patients. J Inherit Metab Dis 2008.Google Scholar
  350. 348.
    Wetterau JR, Aggerbeck LP, Laplaud PM, et al. Structural properties of the microsomal triglyceride-transfer protein complex. Biochemistry. 1991;30:4406–4412.PubMedCrossRefGoogle Scholar
  351. 349.
    Whitley CB, Below KG, Chang PN, et al. Long term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet. 1993;46:209–218.PubMedCrossRefGoogle Scholar
  352. 350.
    Whitley CB, Ramsay NK, Kersey JH, et al. Bone marrow transplantation for Hurler syndrome: Assessment of metabolic correction. Birth Defects Orig Artic Ser. 1986;22:7–24.PubMedGoogle Scholar
  353. 351.
    Willemsen MA, Ijst L, Steijlen PM, et al. Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren-Larsson syndrome. Brain. 2001;124:1426–1437.PubMedCrossRefGoogle Scholar
  354. 352.
    Wisniewski KE. Neuronal Ceroid-Lipofuscinosis. Gene Reviews., May 17, 2006. Accessed June 25, 2008.
  355. 353.
    Wolpert S, Elder D, Scott GI. System of ophthalmology. In: Neuro-Ophthalmology, vol. 12. London: Henry Kimpton; 1971:222.Google Scholar
  356. 354.
    Wong AM, Héon E. Helicoid peripapillary chorioretinal degeneration in abetalipoproteinemia. Arch Ophthalmol. 1998;116:250–251.PubMedGoogle Scholar
  357. 355.
    Wray SH, Cogan DG, Kuwabara T, et al. Adrenoleukodystrophy with disease of the eye and optic nerve. Am J Ophthalmol. 1976;82:480–485.PubMedGoogle Scholar
  358. 356.
    Wulff CH, Trojaborg W. Adult metachromatic leukodystrophy: Neurophysiologic findings. Neurology. 1985;35:1776–1778.PubMedGoogle Scholar
  359. 357.
    Wurtz RH. Vision for the control of eye movement. Invest Ophthalmol Vis Sci. 1996;37:2131–2145.Google Scholar
  360. 358.
    Yee RD, Cogan DG, Zee DS. Ophthalmoplegia and dissociated nystagmus in abetalipoproteinemia. Arch Ophthalmol. 1976;94:571–575.PubMedGoogle Scholar
  361. 359.
    Zee DS, Freeman JM, Holtzman NA. Opthalmoplegia in maple syrup urine disease. J Pediatr. 1974;84:113tt115.PubMedCrossRefGoogle Scholar
  362. 360.
    Zeviani M, Moraes CT, DiMauro S, et al. Deletions of mitochondrial DNA in Kearns–Sayre syndrome. Neurology. 1988;38:1339–1346.PubMedGoogle Scholar
  363. 361.
    Zupanc ML, Chun RW, Gilbert-Barness EF. Osmiophilic deposits in cytosomes in Hallervorden-Spatz syndrome. Pediatr Neurol. 1990;6:345–352.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Michael C. Brodsky
    • 1
  1. 1.Professor of Ophthalmology and NeurologyMayo ClinicRochesterUSA

Personalised recommendations